Biotech's best information is written in a language you don't speak.FuzeBio translates it — into a thesis, a fair value, and a date.
Our agents read the filings, trial registries, and readouts as they publish, then tell you what they mean for the stock — and show you where every claim came from.
Or start with one of these
This is the entire product.
Biotech is the only sector where the primary document is a scientific paper. Here is what that looks like going in, and coming out.
A readout says
“Met its primary endpoint (p<0.001) with a durable complete response in 41% of evaluable patients.”
FuzeBio says
The drug worked, and the result is unlikely to be chance. Tumours disappeared entirely in 41% of patients and stayed gone — the number partners and acquirers price off.
A pipeline update says
“Enrollment in the pivotal Phase 3 trial has completed; topline data are anticipated in Q4.”
FuzeBio says
The readout that decides most of this company’s value lands within about three months. It is on your calendar now, not the morning it prints.
A balance sheet says
“Cash and equivalents of $412M; net cash used in operating activities of $98M for the quarter.”
FuzeBio says
Roughly four quarters of cash against a readout five quarters out. They will likely need to raise before the data — which usually means dilution at a price you won’t like.
7 days free · No card required
Four questions, answered
for any biotech.
What is it actually worth?
Every drug in the pipeline valued on its own with rNPV and DCF, then summed. Change the probability of success, the peak sales, or the discount rate, and the fair value moves with you.
- ✓Bull, base, and bear scenarios
- ✓Your assumptions, not just ours
- ✓Every input shown and adjustable
What's in development, and how close?
The whole pipeline on one screen — preclinical through approval — with the catalyst and expected date attached to each candidate.
- ✓Phase 1 / 2 / 3 / approved at a glance
- ✓Next catalyst marked per drug
Is this drug actually better?
How a candidate compares to the current standard of care and to whatever else is in development for the same indication — and what the difference is worth.
- ✓Measured against standard of care
- ✓Mechanism explained in plain English
Who else is chasing this indication?
The full competitive field for any disease: how large the market is, how it splits by treatment, and every company with a shot at it.
- ✓Addressable market, broken down
- ✓Every competing programme mapped
Most drugs fail. That's the whole problem.
of drugs entering Phase 1 ever reach approval◆ (source: BIO / Informa / QLS, 2011–2020, opens in a new tab)
clear Phase 2 — the hardest gate in the industry◆ (source: BIO / Informa / QLS, 2011–2020, opens in a new tab)
in life-sciences M&A firepower looking for the ones that do◆ (source: EY Firepower M&A Report 2026, opens in a new tab)
Nine in ten drugs that reach human trials never reach a patient. The ones that make it become acquisition targets, and the buyers have never had more cash to spend. Which of the two you are holding is often visible well before the readout — in the trial design, the endpoint chosen, the enrollment rate. It is simply written in a language most investors can't read.
- ◆BIO, Informa Pharma Intelligence & QLS Advisors, “Clinical Development Success Rates and Contributing Factors 2011–2020” (Feb 2021). Based on 12,728 clinical and regulatory phase transitions across 9,704 development programs from 1,779 companies.
- ◆EY, “Firepower M&A Report 2026.” Firepower measures deal capacity from cash and equivalents, debt capacity, and market capitalisation.
Four agents, one report.
Each one does a job an analyst would do by hand. They run when you ask for a ticker, against sources read that moment.
Reads the documents
Filings, trial registries, abstracts, and press releases — read at request time, not recalled from a training set.
SEC, ClinicalTrials.gov, PubMed, FDA
Prices the pipeline
Each drug valued separately, then summed into a fair value you can argue with — because you can change every input.
rNPV, DCF, comparables
Dates the catalysts
Every PDUFA date, advisory committee, and expected readout, tracked against the thesis it would settle.
PDUFA, AdCom, readouts, earnings
Argues both sides
The bull case and the bear case written out in full, so you know exactly what you are betting against.
Probability-weighted scenarios
Valuation models are part of Pro. Everything else is included in the free trial. See what's in each
“Isn't the AI just making this up?”
Fair question, and the right one to ask of anything that writes confident sentences about your money. Three answers.
It reads, it doesn't remember
Every report is generated against documents fetched at that moment. A chatbot answers from a training set that ended months ago; a trial that read out last week is invisible to it.
Every claim keeps its receipt
Numbers link back to the filing, registry entry, or release they came from. If a figure looks wrong, you can go read the source yourself in one click.
You can overrule the model
The fair value is not a verdict. Probability of success, peak sales, and discount rate are all yours to change — and the model recalculates in front of you.
Where the data doesn't exist, the report says so rather than filling the gap. We'd rather show you a hole than a guess.
You already read the science. This is about the four hours after.
If you're already tracking PDUFA dates and parsing endpoints, you don't need the translation — you need the assembly. The model is built by the time you'd have finished pulling the inputs.
- ✓Drug-by-drug rNPV with adjustable PoS and peak sales
- ✓Sum-of-parts waterfalls that update as you edit
- ✓Sensitivity matrices across discount rate and PoS
- ✓The inputs you’d have pulled by hand, already pulled
The alternative isn't cheap.
| Capability | FuzeBio$29/mo | Seeking Alpha$199/yr | Bloomberg$25k/yr | ChatGPT$20/mo |
|---|---|---|---|---|
Adjustable rNPV/DCF models Drug-by-drug models with adjustable PoS, peak sales, discount rates | ✓ | × | – | × |
Plain English, with the methodology shown Trial data explained clearly, and the working kept visible | ✓ | × | × | – |
Live SEC, FDA, and trial data Read at request time from EDGAR, ClinicalTrials.gov, FDA databases | ✓ | × | ✓ | – |
Every claim traceable to a document Follow any number back to the filing or registry it came from | ✓ | – | ✓ | × |
Built for the biotech workflow Pipelines, phases, catalysts, and runway as first-class objects | ✓ | × | × | × |
Hours of reading in seconds Bull and bear cases, catalyst calendars, pipeline views — on request | ✓ | – | ✓ | × |
Adjustable rNPV/DCF models
Drug-by-drug models with adjustable PoS, peak sales, discount rates
Plain English, with the methodology shown
Trial data explained clearly, and the working kept visible
Live SEC, FDA, and trial data
Read at request time from EDGAR, ClinicalTrials.gov, FDA databases
Every claim traceable to a document
Follow any number back to the filing or registry it came from
Built for the biotech workflow
Pipelines, phases, catalysts, and runway as first-class objects
Hours of reading in seconds
Bull and bear cases, catalyst calendars, pipeline views — on request
Start with a ticker you already own.
It's the fastest way to judge this. Pull up a company you think you know well, and see whether the report tells you something you didn't.
Start free trial→7 days free · No card required · Cancel in one click